Invasive micropapillary carcinoma of the breast: clinicopathological and immunohistochemical study. 2004

Clarissa De la Cruz, and Takuya Moriya, and Mareyuki Endoh, and Mika Watanabe, and Junji Takeyama, and Ming Yang, and Mitsue Oguma, and Kazuhiro Sakamoto, and Takashi Suzuki, and Hisashi Hirakawa, and Yojiro Orita, and Noriaki Ohuchi, and Hironobu Sasano
Department of Pathology, Tohoku University Hospital, Sendai, Japan.

Invasive micropapillary carcinoma (IMPCa) of the breast refers to a unique variant of invasive ductal carcinoma, but its biological behavior has not been elucidated well. We analyzed 16 IMPCa cases (10 pure type, six mixed type). The incidence of IMPCa was 1.0% of all primary breast carcinoma. High nuclear grade (75.0%), as well as poorly differentiated histological grade (81.3%), was frequently seen. Lymph node metastases were evident in 92.9% of the examined cases, and about half of them showed more than 10 positive nodes. Comparison between serially experienced invasive ductal carcinoma, not otherwise specified (IDC-NOS), revealed that both high nuclear grade and poor histological grade were significantly more frequent (P < 0001), there was a lower frequency of positive estrogen receptor/progesterone receptor (P < 0.05, P < 0.01), a higher frequency of HER-2 overexpression (P < 0.025), and more frequent lymph node metastases (P < 0.05) in IMPCa. The comparison between lymph node positive IDC-NOS did not show any statistically significant differences in frequency for positive p53, matrix metalloproteinase protein-2 (MMP-2), vascular endothelial growth factor (VEGF) or E-cadherin. However, IMPCa showed a significantly increased number of blood vessels counted by CD34 immunostains (P < 0.05). These results suggest that IMPCa is, at least, the same or more aggressive than lymph node positive cases of IDC-NOS. Hence, not only the high incidence of lymph node metastases but also distant, blood-borne metastases may be important.

UI MeSH Term Description Entries
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002291 Carcinoma, Papillary A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed) Carcinomas, Papillary,Papillary Carcinoma,Papillary Carcinomas
D002467 Cell Nucleus Within a eukaryotic cell, a membrane-limited body which contains chromosomes and one or more nucleoli (CELL NUCLEOLUS). The nuclear membrane consists of a double unit-type membrane which is perforated by a number of pores; the outermost membrane is continuous with the ENDOPLASMIC RETICULUM. A cell may contain more than one nucleus. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed) Cell Nuclei,Nuclei, Cell,Nucleus, Cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D018270 Carcinoma, Ductal, Breast An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST. Carcinoma, Infiltrating Duct,Carcinoma, Invasive Ductal, Breast,Carcinoma, Mammary Ductal,Invasive Ductal Carcinoma, Breast,Mammary Ductal Carcinoma,Carcinomas, Infiltrating Duct,Carcinomas, Mammary Ductal,Mammary Ductal Carcinomas
D019085 Fluorescent Antibody Technique, Direct A form of fluorescent antibody technique utilizing a fluorochrome conjugated to an antibody, which is added directly to a tissue or cell suspension for the detection of a specific antigen. (Bennington, Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984) Immunofluorescence Antibody Test, Direct,Immunofluorescence Technique, Direct,Direct Fluorescent Antibody Technic,Direct Fluorescent Antibody Technique,Direct Immunofluorescence,Direct Immunofluorescence Assay,Fluorescent Antibody Technic, Direct,Immunofluorescence Technic, Direct,Assay, Direct Immunofluorescence,Assays, Direct Immunofluorescence,Direct Immunofluorescence Assays,Direct Immunofluorescence Technic,Direct Immunofluorescence Technics,Direct Immunofluorescence Technique,Direct Immunofluorescence Techniques,Direct Immunofluorescences,Immunofluorescence Assay, Direct,Immunofluorescence Assays, Direct,Immunofluorescence Technics, Direct,Immunofluorescence Techniques, Direct,Immunofluorescence, Direct,Immunofluorescences, Direct

Related Publications

Clarissa De la Cruz, and Takuya Moriya, and Mareyuki Endoh, and Mika Watanabe, and Junji Takeyama, and Ming Yang, and Mitsue Oguma, and Kazuhiro Sakamoto, and Takashi Suzuki, and Hisashi Hirakawa, and Yojiro Orita, and Noriaki Ohuchi, and Hironobu Sasano
March 2015, Oncology letters,
Clarissa De la Cruz, and Takuya Moriya, and Mareyuki Endoh, and Mika Watanabe, and Junji Takeyama, and Ming Yang, and Mitsue Oguma, and Kazuhiro Sakamoto, and Takashi Suzuki, and Hisashi Hirakawa, and Yojiro Orita, and Noriaki Ohuchi, and Hironobu Sasano
December 2011, Pathology international,
Clarissa De la Cruz, and Takuya Moriya, and Mareyuki Endoh, and Mika Watanabe, and Junji Takeyama, and Ming Yang, and Mitsue Oguma, and Kazuhiro Sakamoto, and Takashi Suzuki, and Hisashi Hirakawa, and Yojiro Orita, and Noriaki Ohuchi, and Hironobu Sasano
December 2007, Medical molecular morphology,
Clarissa De la Cruz, and Takuya Moriya, and Mareyuki Endoh, and Mika Watanabe, and Junji Takeyama, and Ming Yang, and Mitsue Oguma, and Kazuhiro Sakamoto, and Takashi Suzuki, and Hisashi Hirakawa, and Yojiro Orita, and Noriaki Ohuchi, and Hironobu Sasano
January 2005, International journal of surgical pathology,
Clarissa De la Cruz, and Takuya Moriya, and Mareyuki Endoh, and Mika Watanabe, and Junji Takeyama, and Ming Yang, and Mitsue Oguma, and Kazuhiro Sakamoto, and Takashi Suzuki, and Hisashi Hirakawa, and Yojiro Orita, and Noriaki Ohuchi, and Hironobu Sasano
January 2024, Archives of medical science : AMS,
Clarissa De la Cruz, and Takuya Moriya, and Mareyuki Endoh, and Mika Watanabe, and Junji Takeyama, and Ming Yang, and Mitsue Oguma, and Kazuhiro Sakamoto, and Takashi Suzuki, and Hisashi Hirakawa, and Yojiro Orita, and Noriaki Ohuchi, and Hironobu Sasano
January 2015, Indian journal of pathology & microbiology,
Clarissa De la Cruz, and Takuya Moriya, and Mareyuki Endoh, and Mika Watanabe, and Junji Takeyama, and Ming Yang, and Mitsue Oguma, and Kazuhiro Sakamoto, and Takashi Suzuki, and Hisashi Hirakawa, and Yojiro Orita, and Noriaki Ohuchi, and Hironobu Sasano
August 2010, Japanese journal of clinical oncology,
Clarissa De la Cruz, and Takuya Moriya, and Mareyuki Endoh, and Mika Watanabe, and Junji Takeyama, and Ming Yang, and Mitsue Oguma, and Kazuhiro Sakamoto, and Takashi Suzuki, and Hisashi Hirakawa, and Yojiro Orita, and Noriaki Ohuchi, and Hironobu Sasano
November 1993, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Clarissa De la Cruz, and Takuya Moriya, and Mareyuki Endoh, and Mika Watanabe, and Junji Takeyama, and Ming Yang, and Mitsue Oguma, and Kazuhiro Sakamoto, and Takashi Suzuki, and Hisashi Hirakawa, and Yojiro Orita, and Noriaki Ohuchi, and Hironobu Sasano
October 2005, Archives of pathology & laboratory medicine,
Clarissa De la Cruz, and Takuya Moriya, and Mareyuki Endoh, and Mika Watanabe, and Junji Takeyama, and Ming Yang, and Mitsue Oguma, and Kazuhiro Sakamoto, and Takashi Suzuki, and Hisashi Hirakawa, and Yojiro Orita, and Noriaki Ohuchi, and Hironobu Sasano
June 2017, Oncotarget,
Copied contents to your clipboard!